(MENAFN- EIN Presswire)
Ankylosing Spondylitis Market
The market value of Ankylosing spondylitis market in 2021 was $5390.79 million
PORTLAND, OREGON, UNITED STATE, July 29, 2022 /EINPresswire.com / -- The global ankylosing spondylitis market size was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6% from 2021 to 2030. The ankylosing spondylitis is an inflammatory disease that can cause some of the bones in the spine (vertebrae) to fuse over time. This fusing makes the spine less flexible and can result in a hunched posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing spondylitis is a complex disorder that can cause some serious complications when left unchecked.
Get Sample Report at: (Flash Sale Tell 20th August 2022):
The global ankylosing spondylitis market size was valued at $5,140.94 million in 2020, and is projected to reach $8,110.59 million by 2030, registering a CAGR of 4.6% from 2021 to 2030. The ankylosing spondylitis is an inflammatory disease that can cause some of the bones in the spine (vertebrae) to fuse over time. This fusing makes the spine less flexible and can result in a hunched posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing spondylitis is a complex disorder that can cause some serious complications when left unchecked.
Key Benefits For Stakeholders
The report provides an in-depth analysis of the global ankylosing spondylitis market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the ankylosing spondylitis market.
A comprehensive analysis of the region assists to understand the regional ankylosing spondylitis market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ankylosing spondylitis market growth.
The ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have a gene called HLA-B27 are at a greatly increased risk of developing ankylosing spondylitis. However, only some people with the gene develop the condition. The ankylosing spondylitis can be diagnosed with physical examination. In addition, MRI and X-ray imaging tests are performed for diagnosis of ankylosing spondylitis.
The ankylosing spondylitis cannot be cured or treated completely but symptoms of disease can be managed with drug treatment and physical exercise. For the management of pain associated with ankylosing spondylitis generally NSAIDs are preferred. In addition, TNF inhibitors, corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are used for management of inflammation in ankylosing spondylitis. Furthermore, monoclonal antibodies has been approved for treatment of ankylosing spondylitis.
The growth of the global ankylosing spondylitis market is majorly driven by an increase in prevalence of ankylosing spondylitis. For instance, according to paper published in Scandinavian Journal of Rheumatology, in 2020, titled 'Prevalence of ankylosing spondylitis in Spain', the study found that about 7.3% population shows positive screening for ankylosing spondylitis. Furthermore, rise in number of orthopedic hospitals and diagnostic centers boost the diagnosis and treatment of diseases. For instance, according to Definitive Healthcare data in 2020 there are more than 30,500 orthopedic surgeons in the U.S.
dominate during the forecast period, owing to rise in prevalence of ankylosing spondylitis, presence of key players for manufacturing & development of drugs for ankylosing spondylitis treatment, and well-established infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.1% from 2021 to 2030, owing to an increase in the number of hospitals, and a high population.
The key players operating in the global ankylosing spondylitis market include AbbVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Eli Lilly and Company, UCB, Inc., Gilead Sciences, Reliance Life Sciences Pvt. Ltd, Janssen Pharmaceuticals, and Merck & Co. Inc.
Key Market Segments
By Drug Class
NSAIDs
TNF inhibitors
Others
By Distribution Channel
Hospital pharmacy
Retail pharmacy
Online pharmacy
By Key Market Players
AbbVie, Inc,
Amgen, Inc,
Eli Lilly and Company
Gilead Sciences
Janssen Pharmaceuticals
Merck & Co. Inc
Novartis AG,
Pfizer, Inc
Reliance Life Sciences Pvt. Ltd
UCB, Inc.,
Ask to Our Industry Expert: (Flash Sale Tell 20th August 2022):
We also Offers Regional and Country Reports-
Japan Ankylosing Spondylitis Market
South Korea Ankylosing Spondylitis Market
Singapore Ankylosing Spondylitis Market
China Ankylosing Spondylitis Market
Indonesia Ankylosing Spondylitis Market
Australia Ankylosing Spondylitis Market
Taiwan Ankylosing Spondylitis Market
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬
Varicella Live Vaccine Market
Safety Needles Market
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions.' AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
MENAFN29072022003118003196ID1104614413
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.